Literature DB >> 12084271

Is it necessary to do staging pelvic lymph node dissection for T1c prostate cancer?

M V Meng1, P R Carroll.   

Abstract

The necessity of pelvic lymph node dissection has been questioned in recent years as a result of improved pre-treatment staging based on clinical and pathologic factors. Accurate evaluation of nodal status allows rational selection of therapy and improved outcomes. Nevertheless, lymph node dissection may play a role even in patients with low stage disease (clinical T1c) despite an overall low risk for metastases. Herein we discuss recent advances in the evaluation of lymph nodes in stage T1c prostate cancer with respect to accurate prediction, radiologic imaging, molecular characterization, and operative considerations.

Entities:  

Mesh:

Year:  2001        PMID: 12084271     DOI: 10.1007/s11934-001-0085-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  35 in total

1.  When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis.

Authors:  M V Meng; P R Carroll
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

2.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.

Authors:  H L Adler; M A McCurdy; M W Kattan; T L Timme; P T Scardino; T C Thompson
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

3.  Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.

Authors:  T Okegawa; K Nutahara; E Higashihara
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

4.  Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study.

Authors:  A F Olumi; J P Richie; D J Schultz; A V D'Amico
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

5.  The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.

Authors:  E D Crawford; J T Batuello; P Snow; E J Gamito; D G McLeod; A W Partin; N Stone; J Montie; R Stock; J Lynch; J Brandt
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

6.  Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.

Authors:  L Salomon; A Hoznek; M A Lefrère-Belda; J Bellot; D K Chopin; C C Abbou
Journal:  Eur Urol       Date:  2000-03       Impact factor: 20.096

7.  Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

Authors:  M J Manyak; G H Hinkle; J O Olsen; R P Chiaccherini; A W Partin; S Piantadosi; J K Burgers; J H Texter; C E Neal; J A Libertino; G L Wright; R T Maguire
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

8.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

Authors:  H B Carter; J I Epstein; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

9.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.